Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, and anemia benefits in intermediate- and high-risk myelofibrosis (MF). Post hoc analyses herein evaluated the efficacy and safety of momelotinib in patients with MF and thrombocyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Gerds, Aaron T., Gupta, Vikas, Verstovsek, Srdan, Egyed, Miklos, Platzbecker, Uwe, Mayer, Jiří, Grosicki, Sebastian, Illés, Árpád, Woźny, Tomasz, Oh, Stephen T., McLornan, Donal, Kirgner, Ilya, Yoon, Sung-Soo, Harrison, Claire N., Klencke, Barbara, Huang, Mei, Kawashima, Jun, Mesa, Ruben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615557/
https://www.ncbi.nlm.nih.gov/pubmed/37908862
http://dx.doi.org/10.1097/HS9.0000000000000963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615557/
https://www.ncbi.nlm.nih.gov/pubmed/37908862
http://dx.doi.org/10.1097/HS9.0000000000000963

Ejemplares similares